249 (ii) The proposed Ordinary Resolution 6 is to seek the shareholders’ approval for the payment of the Directors’ fees to the NonExecutive Directors (NEDs) of the Company in respect of their directorship and committee membership in the Company and any other benefits payable to the NEDs of the Company by the Company with effect from 1 July 2025 until 30 June 2026. The proposed fees for the NEDs of the Company as compared to the existing fees previously approved by the shareholders are as follows: Structure As approved at the Fourteenth AGM Approval sought at the Fifteenth AGM Chairman (RM per annum) Member (RM per annum) Chairman (RM per annum) Member (RM per annum) Board of Directors 660,000 313,500 No change No change Audit Committee 175,000 100,000 No change No change Risk Management Committee 175,000 100,000 No change No change Nomination and Remuneration Committee 175,000 100,000 No change No change Steering Committee (dissolved on 28 November 2024) 350,000 100,000 N/A N/A The benefits provided to the NEDs shall be determined by the Board which presently are comprised of among others, a company car and related benefits for the Chairman, mobile devices and medical benefits. The details of the benefits provided to the NEDs for the financial year ended 31 December 2024 are provided on pages 82 to 83 of the Annual Report 2024. No revision has been proposed in respect of the quantum of the benefits to be provided to the NEDs of the Company from 1 July 2025 until 30 June 2026 as compared to the prior year. (iii) The proposed Ordinary Resolution 7 is to seek the shareholders’ approval for the payment of the Directors’ fees (or its equivalent amount in Ringgit Malaysia as converted using the middle rate of Bank Negara Malaysia foreign exchange on the payment dates, where applicable) to the NEDs of the Company in respect of their directorship and committee membership in the Company’s subsidiaries and any other benefits payable to the NEDs of the Company by the Company’s subsidiaries with effect from 1 July 2025 until 30 June 2026 (except for PTML which shall take retrospective effect from 1 January 2025 until 30 June 2026). PTML has conducted Directors’ fee benchmarking exercise in 2024. PTML Board has approved the changes of Directors’ fees, subject to PTML shareholder’s approval. The changes in Directors’ fees, if approved, shall take retrospective effect from 1 January 2025. The proposed revision to the Directors’ fees in PTML as compared to the existing fees previously approved by the shareholders are as follows: Structure PTML (SGD per annum) As approved at the Fourteenth AGM Approval sought at the Fifteenth AGM Chairman Member Chairman Member Board of Directors 110,000 55,000 120,000 60,000 Audit and Risk Committee 38,000 16,000 40,000 17,000 Nomination and Remuneration Committee 28,000 12,000 31,000 13,000 There is no revision proposed for the Directors’ fees of Fortis Healthcare Limited and ASYH Group. (iv) The NEDs who are shareholders of the Company will abstain from voting on Ordinary Resolutions 6 and 7 regarding the Directors’ fees payable and any other benefits provided by the Company and Company’s subsidiaries to the NEDs of the Company.
RkJQdWJsaXNoZXIy NDgzMzc=